SCHEMBL4628969

SCHEMBL4628969

N=C(NC(=O)c1ccc(Cl)cc1)Nc1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
TRPV1 Q8NER1 1/20 0.56
KMT2A Q03164 7/20 0.52
MEN1 O00255 4/20 0.50
GAA P10253 3/20 0.50
KDM4E B2RXH2 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
EGFR P00533 1/20 0.50
ERBB2 P04626 1/20 0.50
PABPC1 P11940 1/20 0.50
EIF4H Q15056 1/20 0.50
ALDH1A1 P00352 1/20 0.50
ABCC9 O60706 1/20 0.49
ABCC8 Q09428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27447692 0.87 NPC1 (0.76) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL4629282 0.86 RAB9A (0.58) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL4628420 0.85 KCNJ11 (0.52) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL14865820 0.85 NPC1 (0.61) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL4627504 0.82 RORC (0.56) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL3077490 0.78 KDM4E (0.60) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL4657603 0.77 ALDH1A1 (0.70) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL3068433 0.77 KDM4E (0.61) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL1273874 0.75 KDM4E (0.64) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL26885232 0.74 NPC1 (0.81) NPC1RAB9ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA NPC1 140/4885RAB9A 617/4885CYP1A2 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.